Nuance Pharma has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration to begin a Phase III clinical trial of its house dust mite allergy immunotherapy tablet, Actair®, in China.

• The Phase III study is a randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of Actair® over a 12-month treatment period in patients with house dust mite-induced allergic rhinitis, with or without asthma.
• The product was introduced into China’s Hainan Boao Pilot Zone via an early access programme in May 2026, following approval in Macau in January 2026.
• The trial targets patients with house dust mite-induced allergic rhinitis, including those with concomitant asthma.

This summary is based on a press release issued by Nuance Pharma Limited and distributed via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.